OKYO is the ticker symbol for OKYO Pharma Ltd, a publicly traded Healthcare sector company listed on Nasdaq. 13F Pro tracks OKYO with AI-powered analysis, an AI quality score, SEC EDGAR financials, insider transactions, and institutional 13F holdings — all sourced directly from public SEC filings.

Is OKYO a good stock to buy?

OKYO is tracked on 13F Pro with SEC EDGAR data, but is not currently included in our AI quality ranking. The full company profile with financials and AI insights is at https://13fpro.ai/company/OKYO.

Where does 13F Pro source OKYO data?

All OKYO Pharma Ltd fundamentals and ownership data come directly from SEC EDGAR. OKYO Pharma Ltd files with the SEC under CIK 1849296. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

OKYO Pharma Ltd OKYO

NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Below size threshold

Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $0.0M in revenue and is scored on the micro-cap board instead.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Net income

$-8.95M

Quarter to Mar 31

Free cash flow

$-5.94M

Quarter to Mar 31

Top Institutional Holders

as of Q2 2026

$9.74M total

Woodline Partners LP

$5.48M0.0%

Stonepine Capital Management, LLC

$1.29M+1.5%

Maven Securities LTD

$1.21M-31.2%

BALYASNY ASSET MANAGEMENT L.P.

$870.9K-0.7%

Opaleye Management Inc.

$562.8KNew

UBS Group AG

$82.5K-8.0%

XTX Topco Ltd

$56.7K+0.3%

CHOREO, LLC

$49.9KNew

Quantinno Capital Management LP

$49.9KNew

Cerity Partners LLC

$19.2K0.0%

GEODE CAPITAL MANAGEMENT, LLC

$18.1K0.0%

RENAISSANCE TECHNOLOGIES LLC

$16.8KNew

JANE STREET GROUP, LLC

$15.5KNew

Steward Partners Investment Advisory, LLC

$9.0KNew

EFG International AG

$1.4K0.0%

OSAIC HOLDINGS, INC.

$2280.0%

Continuum Advisory, LLC

$75New

MORGAN STANLEY

$150.0%

Caitong International Asset Management Co., Ltd

$4New

See all 19 institutional holders →

Reading the latest SEC filing…

Key Metrics

Net Income

FY 2026

EDGAR

EPS (Diluted)

FY 2026

EDGAR

ROIC

FY 2026

EDGAR

Free Cash Flow

FY 2026

EDGAR

Loading ratio trend…

OKYO insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

Patil Rajkumar V.Chief Scientific OfficerGrant or award · Jul 27, 2026
Dempsey Robert JohnCHIEF EXECUTIVE OFFICERGrant or award · Jul 22, 2026
Brancaccio John PDirectorGrant or award · Jul 21, 2026
Jacob Gary SCHIEF DEVELOPMENT OFFICERGrant or award · Jul 21, 2026
Cerrone Gabriele MDirectorGrant or award · Jul 21, 2026
Mantelli FlavioCHIEF MEDICAL OFFICERGrant or award · Jul 21, 2026
Shah Keeren RameshchandraChief Financial OfficerGrant or award · Jun 8, 2026
Simon Willy JulesDirectorGrant or award · Jun 8, 2026
Denoyer BernardDirectorGrant or award · Jun 8, 2026

About OKYO Pharma Ltd (OKYO): stock profile, AI score and financials

OKYO Pharma Ltd (OKYO) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. OKYO is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.0m in revenue and is scored on the micro-cap board instead. Based on the latest XBRL financial filings (FY 2026), OKYO Pharma Ltd reports net income of $-8.9M, free cash flow of $-5.9M. Top institutional holders of OKYO by reported 13-F value include Woodline Partners, Stonepine Capital Management, Maven Securities LTD, based on the most recent SEC filings. OKYO trades on the Nasdaq exchange and files with the SEC under CIK 1849296. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate OKYO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for OKYO Pharma Ltd directly from SEC EDGAR.

SEC EDGAR: CIK 1849296 →